Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Authors
Keywords
-
Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 95, Issue 4, Pages 347-355
Publisher
Wiley
Online
2017-01-31
DOI
10.1038/icb.2017.6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
- (2016) Carmen Martínez et al. BRITISH JOURNAL OF HAEMATOLOGY
- PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors
- (2016) Roxanne Charlebois et al. CANCER RESEARCH
- IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
- (2016) Elizabeth L. McMichael et al. CLINICAL CANCER RESEARCH
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
- (2016) Laura Q.M. Chow et al. CLINICAL CANCER RESEARCH
- Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
- (2016) JP Laubach et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
- (2016) Julio C. Chavez et al. LEUKEMIA RESEARCH
- Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
- (2016) Joerg U Schmohl et al. MOLECULAR THERAPY
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Dinutuximab: A Review in High-Risk Neuroblastoma
- (2016) Sheridan M. Hoy Targeted Oncology
- Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
- (2016) Stephen R. Adams et al. Nature Communications
- Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
- (2016) Mattias Carlsten et al. Frontiers in Immunology
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
- (2016) Holbrook E. Kohrt et al. Journal for ImmunoTherapy of Cancer
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
- (2016) Jérôme Fayette et al. Frontiers in Oncology
- The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
- (2015) M. Rosario et al. CLINICAL CANCER RESEARCH
- Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma
- (2015) M. J. Barth et al. CLINICAL CANCER RESEARCH
- Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
- (2015) V. Gonzalez-Nicolini et al. CLINICAL CANCER RESEARCH
- Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
- (2015) Suman Mitra et al. IMMUNITY
- Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
- (2015) E Muraro et al. Journal of Translational Medicine
- Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*
- (2015) Matt E. Kalaycio et al. LEUKEMIA & LYMPHOMA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
- (2015) Michela Croce et al. Journal of Immunology Research
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- (2014) Vassiliki Saloura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- TGF- Utilizes SMAD3 to Inhibit CD16-Mediated IFN- Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells
- (2014) R. Trotta et al. JOURNAL OF IMMUNOLOGY
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
- (2014) Kristen N. Ganjoo et al. LEUKEMIA & LYMPHOMA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF- -inducible microRNA-183 silences tumor-associated natural killer cells
- (2014) S. S. Donatelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
- (2013) Jean-Pierre Delord et al. EUROPEAN JOURNAL OF CANCER
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency
- (2013) Marie Vincent et al. INTERNATIONAL JOURNAL OF CANCER
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+head and neck cancer cells
- (2013) Chwee Ming Lim et al. OncoImmunology
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer
- (2012) N Steele et al. BRITISH JOURNAL OF CANCER
- Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein
- (2012) M. C. Ochoa et al. CANCER RESEARCH
- GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
- (2012) C. A. Gerdes et al. CLINICAL CANCER RESEARCH
- Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells
- (2012) Xuewen Deng et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
- (2012) P Glorius et al. LEUKEMIA
- Inhibition of TGF- Enhances the In Vivo Antitumor Efficacy of EGF Receptor-Targeted Therapy
- (2012) A. Bedi et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
- (2011) S. Veeramani et al. BLOOD
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
- (2011) W. G. Wierda et al. BLOOD
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
- (2010) Caroline J Voskens et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
- (2010) Linda S. Sorkin et al. PAIN
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
- (2009) J. A. Hank et al. CLINICAL CANCER RESEARCH
- Natural killer cell recognition of missing self
- (2008) Klas Kärre NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started